Literature DB >> 13929797

Chromatographic resolution of the first component of human complement into three activities.

I H LEPOW, G B NAFF, E W TODD, J PENSKY, C F HINZ.   

Abstract

A euglobulin fraction of human C'1 has been chromatographically resolved into three distinct activities, designated C'1q, C'1r, and C'1s, in the order of their elution from DEAE cellulose. All three of these activities have been shown to participate in various hemolytic reactions requiring C'1, including the cold phase of the Donath-Landsteiner reaction, and to be necessary for generation of C'1 esterase. C'1q was identical with a previously described serum protein implicated in a very early step of complement action and designated the 11S component on the basis of its sedimentation constant. C'1r could not be related to a known complement activity and has been presented as a new component. C'1s, on the basis of chromatographic evidence, was identified with C'1 proesterase. Methods of assay of these components of C'1 have been presented. The significance of C'1q, C'1r, and C'1s in generation of C'1 esterase and the central role of this enzyme in reactions involving C'1, C'4, and C'2 have been discussed.

Entities:  

Keywords:  COMPLEMENT

Mesh:

Substances:

Year:  1963        PMID: 13929797      PMCID: PMC2137589          DOI: 10.1084/jem.117.6.983

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  25 in total

1.  Third component of human complement: resolution into two factors and demonstration of a new reaction intermediate.

Authors:  A B TAYLOR; M A LEON
Journal:  Proc Soc Exp Biol Med       Date:  1959-07

2.  Isolation of a thermolabile serum protein which precipitates gamma-globulin aggregates and participates in immune hemolysis.

Authors:  H J MULLER-EBERHARD; H G KUNKEL
Journal:  Proc Soc Exp Biol Med       Date:  1961-02

3.  Assay and properties of serum inhibitor of C'l-esterase.

Authors:  L R LEVY; I H LEPOW
Journal:  Proc Soc Exp Biol Med       Date:  1959 Aug-Sep

4.  Complex nature of the step in immune hemolysis involving third component of complement.

Authors:  K AMIRAIAN; O J PLESCIA; G CAVALLO; M HEIDELBERGER
Journal:  Science       Date:  1958-01-31       Impact factor: 47.728

5.  Observations on a pro-esterase associated with partially purified first component of human complement (C'1).

Authors:  I H LEPOW; O D RATNOFF; F S ROSEN; L PILLEMER
Journal:  Proc Soc Exp Biol Med       Date:  1956-05

6.  Interaction of a serum inhibitor of C'I-esterase with intermediate complexes of the immune haemolytic system. I. Specificity of inhibition of C'I activity associated with intermediate complexes.

Authors:  I H LEPOW; M A LEON
Journal:  Immunology       Date:  1962-03       Impact factor: 7.397

7.  Quantitative studies on the properdin-complement system. II. Kinetics of the reaction between properdin and zymosan.

Authors:  M A LEON
Journal:  J Exp Med       Date:  1957-05-01       Impact factor: 14.307

8.  Studies on immune cellular injury. II. Functional role of C'1 esterase in immune cytotoxicity.

Authors:  I H LEPOW; A ROSS
Journal:  J Exp Med       Date:  1960-12-01       Impact factor: 14.307

9.  The cytotoxic action of immune gamma globulin and complement on Krebs ascites tumor cells. II. Chemical studies.

Authors:  H GREEN; R A FLEISCHER; P BARROW; B GOLDBERG
Journal:  J Exp Med       Date:  1959-05-01       Impact factor: 14.307

10.  STUDIES ON IMMUNE HUMAN HEMOLYSIS : II. THE DONATH-LANDSTEINER REACTION AS A MODEL SYSTEM FOR STUDYING THE MECHANISM OF ACTION OF COMPLEMENT AND THE ROLE OF C'1 AND C'1 ESTERASE.

Authors:  C F Hinz; M E Picken; I H Lepow
Journal:  J Exp Med       Date:  1961-01-01       Impact factor: 14.307

View more
  109 in total

1.  STUDIES ON THE ANTIGENIC PROPERTIES OF COMPLEMENT. III. SPECIFIC INACTIVATION OF CELL-FIXED COMPONENTS OF GUINEA-PIG COMPLEMENT BY ANTI-COMPLEMENT.

Authors:  W OPFERKUCH; P G KLEIN
Journal:  Immunology       Date:  1964-05       Impact factor: 7.397

2.  CHARACTERIZATION OF A GENETICALLY IDENTIFIABLE COMPONENT OF COMPLEMENT IN MICE.

Authors:  D K TACHIBANA; L T ROSENBERG
Journal:  Folia Microbiol (Praha)       Date:  1964-05       Impact factor: 2.099

3.  BIOLOGIC PROPERTIES OF POLYNUCLEOTIDES. IV. STUDIES ON THE MECHANISM OF COMPLEMENT INHIBITION BY POLYINOSINIC ACID TOGETHER WITH OBSERVATIONS ON THE IN VIVO EFFECT OF POLYINOSINIC ACID ON COMPLEMENT ACTIVITY.

Authors:  S YACHNIN; D ROSENBLUM
Journal:  J Clin Invest       Date:  1964-06       Impact factor: 14.808

4.  ACTION OF COMPLEMENT IN HEREDITARY ANGIONEUROTIC EDEMA: THE ROLE OF C'1-ESTERASE.

Authors:  V H DONALDSON; F S ROSEN
Journal:  J Clin Invest       Date:  1964-11       Impact factor: 14.808

5.  PH OPTIMA IN IMMUNE HEMOLYSIS: A COMPARISON BETWEEN GUINEA PIG AND HUMAN COMPLEMENT.

Authors:  S YACHNIN; J M RUTHENBERG
Journal:  J Clin Invest       Date:  1965-01       Impact factor: 14.808

6.  THE ELUTION OF S35-LABELLED C'1 FROM ANTIGEN-ANTIBODY-S35 COMPLEMENT PRECIPITATES.

Authors:  L KORNFELD; W O WEIGLE
Journal:  Immunology       Date:  1965-02       Impact factor: 7.397

7.  THE HEMOLYSIS OF RED CELLS FROM PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA BY PARTIALLY PURIFIED SUB-COMPONENTS OF THE THIRD COMPLEMENT COMPONENT.

Authors:  S YACHNIN
Journal:  J Clin Invest       Date:  1965-09       Impact factor: 14.808

8.  INHIBITION OF COMPLEMENT BY CARRAGEENIN: MODE OF ACTION, EFFECT ON ALLERGIC REACTIONS AND ON COMPLEMENT OF VARIOUS SPECIES.

Authors:  G E DAVIES
Journal:  Immunology       Date:  1965-03       Impact factor: 7.397

9.  Antibody-independent and -dependent opsonization of group B Streptococcus requires the first component of complement C1.

Authors:  N J Levy; D L Kasper
Journal:  Infect Immun       Date:  1985-07       Impact factor: 3.441

10.  Heterogeneity, polypeptide chain composition and antigenic reactivity of autoantibodies (F-42) that are directed against the classical pathway C3 convertase of complement and isolated from sera of patients with systemic lupus erythematosus.

Authors:  M R Daha; H M Hazevoet; L A van Es
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.